-+ 0.00%
-+ 0.00%
-+ 0.00%
H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
Share
Listen to the news

U.S. stocks were lower, with the Nasdaq Composite falling around 500 points on Monday.

Shares of H World Group Limited (NASDAQ:HTHT) rose sharply after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance.

H World Group reported quarterly earnings of 93 cents per share which beat the analyst consensus estimate of 78 cents per share. The company reported quarterly sales of $1.156 billion which beat the analyst consensus estimate of $1.140 billion.

H World Group shares jumped 9.3% to $55.08 on Monday.

Here are some other big stocks recording gains in today’s session.

  • mF International Limited (NASDAQ:MFI) shares jumped 17.1% to $8.89.
  • CG Oncology, Inc. (NASDAQ:CGON) rose 12% to $83.35 after the company announced PIVOT-006 achieved its primary endpoint.
  • TELUS Corporation (NYSE:TU) gained 11.9% to $9.55 after Québecor submitted an unsolicited, non-binding, and conditional proposal to acquire the company.
  • Bgin Blockchain Limited (NASDAQ:BGIN) gained 10.7% to $4.2900.
  • Katapult Holdings, Inc. (NASDAQ:KPLT) gained 9.7% to $9.69.
  • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 8.9% to $4.6950.
  • Tyson Foods, Inc. (NYSE:TSN) climbed 8.5% to $63.82 as the company posted better-than-expected earnings for the fourth quarter.
  • Fennec Pharmaceuticals Inc. (NASDAQ:FENC) climbed 8.4% to $12.60 after B. Riley Securities raised its price target on the stock from $18 to $19.
  • Molina Healthcare, Inc. (NYSE:MOH) gained 8.3% to $226.79.
  • AEVEX Corp. (NYSE:AVEX) rose 8.1% to $13.52.
  • Zevra Therapeutics, Inc. (NASDAQ:ZVRA) gained 6.2% to $9.65. Guggenheim analyst Eddie Hickman maintained Zevra Therapeutics with a Buy and lowered the price target from $23 to $18.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending